Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-04
-
The potential existence of ER stress was first examined in
2019-08-17
The potential existence of ER stress was first examined in EVTs in placental bed biopsy specimens obtained from pregnancies complicated by early-onset preeclampsia. It was then tested whether ER stress can modulate MMP-2 activity before elucidating the role of proinflammatory cytokines in the induct
-
br Results br Discussion Adult hand foot and
2019-08-17
Results Discussion Adult hand, foot and mouth disease gets no particular research interest because it has been seen as a sporadic mild viral infection that spontaneously resolved in a few days. However, evidence showed that adults may act as latent enterovirus reservoirs. A serum epidemiologic
-
Tubastatin A Dexamethasone DEX a potent synthetic
2019-08-17
Dexamethasone (DEX), a potent synthetic glucocorticoid drug, is effective for treatment of a range of inflammatory and autoimmune conditions as well as the reduction of side effects associated with chemotherapy. On the Czech Republic pharmaceutical market, DEX is incorporated into eighteen drugs use
-
In BBR was reported to increase LDL
2019-08-17
In 2004, BBR was reported to increase LDL receptor (LDLR) gene expression by stabilizing LDLR mRNA [4]. Following this report, the same groups conducted additional studies predominantly in HepG2 cells, with similar effects being observed [8], [11], [12], [4]. In addition to LDLR-mediated LDL cholest
-
br Concluding remarks Some of the clinical trials
2019-08-17
Concluding remarks Some of the clinical trials of putative neutral competitive ERAs have been less successful than anticipated 6, 8, 11. This might be because of underestimation of the complexity of the molecular pharmacology of ETA. To resolve this, it will be necessary to define the signaling m
-
Recent pharmacological and clinical studies suggested that
2019-08-17
Recent pharmacological and clinical studies suggested that estetrol (E4) should also be considered as an interesting candidate for MHT (Abot et al., 2014; Mawet et al., 2015). E4 is naturally produced from E2 and estriol (E3) via 15α- and 16α-hydroxylase by the human fetal liver during pregnancy and
-
Introduction Hematopoietic stem cells HSCs
2019-08-17
Introduction Hematopoietic stem Nilotinib in (HSCs) in the adult bone marrow (BM) provide all types of blood cells throughout life, while also self-renewing to maintain blood homeostasis. Blood/marrow stem cell transplantation is the most advanced method to cure patients suffering from hematologic
-
ApoE is secreted from astrocytes glia into the
2019-08-17
ApoE is secreted from astrocytes/glia into the interstitial fluid and is important for metabolizing Aβ because of its propensity for binding Aβ as a cholesterol and phospholipid acceptor in reverse cholesterol transport [8]. Aβ oligomers show a direct toxicity to neurons, and ApoE inhibits oligomer
-
ELUXA HM EMSI is an ongoing pivotal Phase II
2019-08-17
ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp
-
br Conflicts of interest br Acknowledgements br Introduction
2019-08-17
Conflicts of interest Acknowledgements Introduction Atherosclerosis is the number one cause of death in the United States and among the leading causes of morbidity and mortality globally [1]. Inflammation is critical in all stages of atherosclerosis from the formation of a plaque in the ves
-
The goal of studying RvE in goblet cells is to
2019-08-17
The goal of studying RvE1 in goblet amphetamine sulfate is to determine if it may be used to preserve ocular surface homeostasis and as a treatment of ocular inflammatory diseases. We found that RvE1 increased glycoconjugate secretion after 2 h, not at 4 h. This suggests that RvE1 has a short, but
-
homoharringtonine in The estrogen receptor ER dependent
2019-08-17
The estrogen receptor(ER)-dependent signaling pathway plays an important role in bone metabolism by restoring the balance between osteoblastic bone formation and osteoclastic bone resorption [21]. ER has two major isoforms, ERalpha (ER-α) and ERbeta (ER-β), which mediate the effect of estrogen and o
-
The data from drug screening in
2019-08-17
The data from drug screening in P. berghei (Fig. 3D) provide proof of concept that chemogenomic profiling can be accomplished in P. berghei in the same manner as P. falciparum, in that significant increases in the EC50 ratio were found only for antifolate drugs in the parasite with attenuated TgDHFR
-
A range of therapies exists for the treatment of
2019-08-17
A range of therapies exists for the treatment of inflammation-driven diseases, which can be summarized as non-steroidal anti-inflammatory drugs (NSAIDs), corticoids and steroidal-related drugs (Ward et al., 2008). Despite of these notable successes, there are still major unmet medical needs in the t
-
It has been reported that CysLT receptors
2019-08-17
It has been reported that CysLT2 receptors negatively regulate CysLT1 receptor-mediated response in allergic airway inflammation in mice. Knockdown of CysLT2 receptors augmented CysLT1 receptor-mediated mast cell proliferation [31] and eosinophilic airway inflammation induced by antigen challenge in
15957 records 977/1064 page Previous Next First page 上5页 976977978979980 下5页 Last page